Targeting acute myeloid leukemia with a proapoptotic peptide conjugated to a toll-like receptor 2-mediated cell-penetrating peptide

International Journal of Cancer

Volumn 134, Issue 3, 2014, Pages 692-702

  Li, Ke ^a   Lv, Xiao Xi ^a   Hua, Fang ^a   Lin, Heng ^a   Sun, Wei ^a   Cao, Wen Bin ^b   Fu, Xiao Ming ^a   Xie, Jing ^a   Yu, Jiao Jiao ^a   Li, Zhe ^a   Liu, Hong ^a   Han, Ming Zhe ^b   Hu, Zhuo Wei ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

Author keywords

apoptosis; cancer therapy; cell penetrating peptide; targeted drug delivery

Indexed keywords

ANTILEUKEMIC AGENT; CELL PENETRATING PEPTIDE; PEP2 ASPARTIC ACID(LYSYLLEUCYLALANYLLYSYLLEUCYLALANYLLYSINE) 2 CONJUGATE; TOLL LIKE RECEPTOR 2; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTILEUKEMIA ACTIVITY; APOPTOSIS; ARTICLE; BINDING SITE; BIOPANNING; BONE MARROW; CANCER GROWTH; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG PENETRATION; DRUG TARGETING; EMBRYO; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA CELL; MOUSE; NONHUMAN; PEPTIDE LIBRARY; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF;

EID: 84888005260     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28382     Document Type: Article

References (46)

1. McDaniel JM, Pinilla-Ibarz J, Epling-Burnette PK,. Molecular action of lenalidomide in lymphocytes and hematologic malignancies. Adv Hematol 2012: 1-9.
2. O'Connor OA, Czuczman MS,. Novel approaches for the treatment of NHL: proteasome inhibition and immune modulation. Leuk Lymphoma 2008; 49: S59-S66.
3. Hagenbeek A, Gadeberg O, Johnson P, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 2008; 111: 5486-95.
4. Cheson B,. Monoclonal antibody therapy of chronic lymphocytic leukemia. Cancer Immunol Immunother 2006; 55: 188-96.
5. DiJoseph JF, Armellino DC, Boghaert ER, et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 2004; 103: 1807-14.
6. Jager E, van der Velden VHJ, te Marvelde JG, et al. Targeted drug delivery by gemtuzumab ozogamicin: mechanism-based mathematical model for treatment strategy improvement and therapy individualization. PLoS One 2011; 6: e24265.
7. Walter RB, Medeiros BC, Powell BL, et al. Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia. Haematologica 2012; 97: 739-42.
8. Guzman ML, Rossi RM, Neelakantan S, et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 2007; 110: 4427-35.
9. Hassane DC, Sen S, Minhajuddin M, et al. Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways. Blood 2010; 116: 5983-90.
10. Guzman ML, Rossi RM, Karnischky L, et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 2005; 105: 4163-9.
11. Robillard N, Wuilleme S, Lode L, et al. CD33 is expressed on plasma cells of a significant number of myeloma patients, and may represent a therapeutic target. Leukemia 2005; 19: 2021-2.
12. Jedema I, Barge RMY, van der Velden VHJ, et al. Internalization and cell cycle-dependent killing of leukemic cells by gemtuzumab ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia 2003; 18: 316-25.
13. Zhang H, Luo J, Li Y, et al. Characterization of high-affinity peptides and their feasibility for use in nanotherapeutics targeting leukemia stem cells. Nanomed Nanotechnol Bio Med 2011; 8: 1116-24.
14. Koren E, Apte A, Sawant RR, et al. Cell-penetrating TAT peptide in drug delivery systems: proteolytic stability requirements. Drug Deliv 2011; 18: 377-84.
15. Nasrollahi SA, Taghibiglou C, Azizi E, et al. Cell-penetrating peptides as a novel transdermal drug delivery system. Chem Biol Drug Design 2012; 80: 639-46.
16. Meade BR, Dowdy SF,. Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides. Adv Drug Deliv Rev 2007; 59: 134-40.
17. Madani F, Lindberg S, Langel Ü, et al. Mechanisms of cellular uptake of cell-penetrating peptides. J Biophys 2011; 2011: 414729.
18. Gooding M, Browne LP, Quinteiro FM, et al. siRNA delivery: from lipids to cell penetrating peptides and their mimics. Chem Biol Drug Design 2012; 80: 787-809.
19. van Luijn MM, van de Loosdrecht AA, Lampen MH, et al. Promiscuous binding of invariant chain-derived CLIP peptide to distinct HLA-I molecules revealed in leukemic cells. PLoS One 2012; 7: e34649.
20. Jager S, Jahnke A, Wilmes T, et al. Leukemia targeting ligands isolated from phage display peptide libraries. Leukemia 2007; 21: 411-20.
21. Zähringer U, Lindner B, Inamura S, et al. TLR2-promiscuous or specific? A critical re-evaluation of a receptor expressing apparent broad specificity. Immunobiology 2008; 213: 205-24.
22. Pålsson-McDermott E, O'Neill L,. The potential of targeting Toll-like receptor 2 in autoimmune and inflammatory diseases. Ir J Med Sci 2007; 176: 253-60.
23. Tye H, Kennedy Catherine L, Najdovska M, et al. STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell 2012; 22: 466-78.
24. Egger L, Schneider J, Rhême C, et al. Serine proteases mediate apoptosis-like cell death and phagocytosis under caspase-inhibiting conditions. Cell Death Differ 2003; 10: 1188-203.
25. Xie W, Wang Y, Huang Y, et al. Toll-like receptor 2 mediates invasion via activating NF-κB in MDA-MB-231 breast cancer cells. Biochem Biophys Res Commun 2009; 379: 1027-32.
26. Nihon-Yanagi Y, Terai K, Murano T, et al. Tissue expression of Toll-like receptors 2 and 4 in sporadic human colorectal cancer. Cancer Immunol Immunother 2012; 61: 71-7.
27. Yang H-Z, Cui B, Liu H-Z, et al. Blocking TLR2 activity attenuates pulmonary metastases of tumor. PLoS One 2009; 4: e6520.
28. Lin H, Yan J, Wang Z, et al. Loss of Immunity-supported senescence enhances susceptibility to hepatocellular carcinogenesis and progression in TLR2-deficient mouse. Hepatology 2013; 57: 171-82.
29. Javadpour MM,. De novo antimicrobial peptides with low mammalian cell toxicity. J Med Chem 1996; 39: 3107-13.
30. Ellerby HM, Arap W, Ellerby LM, et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 1999; 5: 1032-8.
31. Standley SM, Toft DJ, Cheng H, et al. Induction of cancer cell death by self-assembling nanostructures incorporating a cytotoxic peptide. Cancer Res 2010; 70: 3020-6.
32. Giordano RJ,. Biopanning and rapid analysis of selective interactive ligands. Nat Med 2001; 7: 1249-53.
33. Karjalainen K, Jaalouk DE, Bueso-Ramos CE, et al. Targeting neuropilin-1 in human leukemia and lymphoma. Blood 2011; 117: 920-7.
34. Arvaniti E, Ntoufa S, Papakonstantinou N, et al. Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients. Haematologica 2011; 96: 1644-52.
35. Smits ELJM, Ponsaerts P, Berneman ZN, et al. The Use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist 2008; 13: 859-75.
36. Spaner DE, Shi Y, White D, et al. A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia. Leukemia 2009; 24: 222-6.
37. Trabulo S, Cardoso AL, Mano M, et al. Cell-penetrating peptides-mechanisms of cellular uptake and generation of delivery systems. Pharmaceuticals 2010; 3: 961-93.
38. Deshayes S, Morris M, Heitz F, et al. Delivery of proteins and nucleic acids using a non-covalent peptide-based strategy. Adv Drug Deliv Rev 2008; 60: 537-47.
39. Pecora ND, Gehring AJ, Canaday DH, et al. Mycobacterium tuberculosis LprA is a lipoprotein agonist of TLR2 that regulates innate immunity and APC function. J Immunol 2006; 177: 422-9.
40. Lancioni CL, Li Q, Thomas JJ, et al. Mycobacterium tuberculosis lipoproteins directly regulate human memory CD4+ T cell activation via toll-like receptors 1 and 2. Infect Immun 2011; 79: 663-73.
41. Hayes JD, Pulford DJ,. The glutathione S-transferase supergene family: regulation of GST and the contribution of the lsoenzymes to cancer chemoprotection and drug resistance Part II. Crit Rev Biochem Mol Biol 1995; 30: 521-600.
42. Dantzig AH, Bergin L,. Uptake of the cephalosporin, cephalexin, by a dipeptide transport carrier in the human intestinal cell line, Caco-2. Biochim Biophys Acta 1990; 1027: 211-17.
43. Xu C, Fan J, Riekhof W, et al. A permease-like protein involved in ER to thylakoid lipid transfer in Arabidopsis. EMBO J 2003; 22: 2370-9.
44. Galluzzi L, Larochette N, Zamzami N, et al. Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene 2006; 25: 4812-30.
45. Kosuge M, Takeuchi T, Nakase I, et al. Cellular internalization and distribution of arginine-rich peptides as a function of extracellular peptide concentration, #serum, and plasma membrane associated proteoglycans. Bioconjug Chem 2008; 19: 656-64.
46. Mai JC, Mi Z, Kim S-H, et al. A proapoptotic peptide for the treatment of solid tumors. Cancer Res 2001; 61: 7709-12.